<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Selective adsorption is a new method of treating <z:e sem="disease" ids="C0018378" disease_type="Disease or Syndrome" abbrv="">Guillain-Barré syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Its therapeutic effects and its concomitant side effects were compared between plasma exchange and symptomatic treatment only </plain></SENT>
<SENT sid="2" pm="."><plain>The clinical study of three groups of 10 Guillain-Barré patients, each matched for age and maximal disability, was analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>Selective adsorption compared favorably with plasma exchange in shortening the time to first improvement and duration of in-hospital treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Side effects were similar in both groups </plain></SENT>
<SENT sid="5" pm="."><plain>Symptomatic <z:hpo ids='HP_0002634'>arteriosclerosis</z:hpo> should be considered a relative contraindication for selective adsorption </plain></SENT>
</text></document>